Black Hawk Secures $200M Equity Line and Backstop Financing Ahead of Vesicor Merger Vote
BKHA sits 21% above its 52-week low of $10.09 on light trading volume (0.2× avg).
Summary
Black Hawk Acquisition Corp entered into a $200M equity line and backstop financing package with Meteora to support its pending Vesicor merger, two days before the filing.
Updates
· SEC 425 — The 425 details a $200M standby equity purchase agreement with 97% pricing, a forward purchase for up to 1,350,000 shares at $10 reset, a non-redemption backstop for up to 2,124,077 shares, and a subscription agreement.
Key Events · Financing and Capital Events · BKHA
-
$200M Standby Equity Purchase Agreement
PubCo will have the right to sell up to $200M of common stock to Meteora over 36 months (extendable by 24 months) at 97% of market price, with no mandatory minimum utilization.
-
Forward Purchase Agreement
Covers up to 1,350,000 shares with a $10.00 reset price, subject to upward adjustment on dilutive offerings; Meteora waives redemption rights on recycled shares.
-
Non-Redemption Agreement
Meteora agrees on a best-efforts basis to hold up to 2,124,077 shares and not redeem them, receiving the redemption price less $0.75 per share from the trust account.
-
Convertible Note Terms
Pre-paid advances funded at 85% of face value (15% OID), 12-month maturity, 7% payment premium, and conversion at the lower of fixed price or 95% of lowest 5-day VWAP.
Analysis · BKHA · Life Sciences
Two days before this filing, on September 22, 2026, Black Hawk Acquisition Corp entered into a package of financing agreements with Meteora Select Trading Opportunities Master, LP. The centerpiece is a $200 million Standby Equity Purchase Agreement (SEPA) that gives the post-merger company the right, but not the obligation, to sell shares to Meteora over 36 months. The package also includes a Forward Purchase Agreement covering up to 1,350,000 shares, a Non-Redemption Agreement covering up to 2,124,077 shares, and a Subscription Agreement. These agreements are designed to shore up the SPAC's trust account and reduce redemptions ahead of the October 13 shareholder vote on the Vesicor merger. The SEPA's convertible promissory note terms include a 15% original issue discount, a 7% payment premium, and a variable conversion price at 95% of the lowest daily VWAP over five trading days — terms that are dilutive to existing shareholders if utilized. Against the backdrop of Black Hawk's going concern warning, ineffective internal controls, and Nasdaq delisting notice disclosed in its July 10-Q, this financing package is a survival move that removes near-term liquidity risk but introduces significant potential dilution.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BKHA was trading at $12.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.6M. The 52-week trading range was $10.09 to $13.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.